Ventus Therapeutics raised a $140m series C while Endeavor Biomedicines brought in $101m in series B cash. Also, Twist Bioscience grossed $250m in a follow-on offering, BioMarin raised $110m when it sold a priority review voucher and Nuvectis, TC BioPharm launched IPOs. 

Japanese firm again links with an earlier venture capital partner and some familiar faces to progress its norovirus vaccine outside Japan.

Pharma moves Phase III-ready antibody to prevent pneumonia to Aridis, licenses preclinical STING inhibitors from F-star. Sanofi teams with SRI on AI-directed discovery, Biogen licenses BTK inhibitor from InnoCare.

Altimmune’s hopes of bringing a nasal COVID-19 vaccine to market have been dashed, but it is pivoting to novel peptide-based therapies.